We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Thermo Fisher Scientific - Direct Effect Media

Download Mobile App




Events

ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.

Wearable Cardioverter Defibrillator System Protects Patients at Risk of Sudden Cardiac Arrest

By HospiMedica International staff writers
Posted on 13 Apr 2022
Print article
Image: ASSURE WCD system was one of the winners of the 2022 Medical Design Excellence Awards (Photo courtesy of Kestra Medical)
Image: ASSURE WCD system was one of the winners of the 2022 Medical Design Excellence Awards (Photo courtesy of Kestra Medical)

Sudden cardiac arrest is a leading cause of death. SCA is an abrupt cessation of the normal heartbeat that is triggered by an electrical malfunction in the heart, typically caused by ventricular arrhythmias. It can lead to a loss of consciousness and potentially death within minutes if not treated. Heart failure (HF) patients and patients with low left ventricular ejection fraction (low LVEF) of 35% or below are at elevated risk of SCA while waiting for their condition to improve or until eligible for subsequent therapy. Wearable Cardioverter Defibrillators (WCDs) are non-invasive, monitor around the clock, and can protect patients who are at known risk for SCA

The ASSURE system from Kestra Medical Technologies (Kirkland, WA, USA) represents the next generation of monitoring and therapy to protect patients at risk of SCA. It includes a wearable device that provides autonomous detection and defibrillation for ventricular arrhythmias, if needed. The complete Cardiac Recovery System includes the ASSURE WCD, the ASSURE patient app, and Kestra CareStation remote patient data platform, all working together to provide comfortable protection for patients and clear insights for providers. The ASSURE WCD system received Food and Drug Administration premarket approval in 2021 and was also recognized as one of the winners of the 2022 Medical Design Excellence Awards (MDEA).

Related Links:
Kestra Medical Technologies 


Print article

Channels

Critical Care

view channel
Image: EsoGuard has demonstrated over 90% specificity and 90% sensitivity in identifying Barrett’s Esophagus (Photo courtesy of Lucid Diagnostics)

Biomarker Based Non-Endoscopic Technology Identifies Risk for Esophageal Cancer

Barrett's esophagus (BE) is the benign and treatable precursor condition to esophageal adenocarcinomas (EAC) which is usually diagnosed at an advanced stage and is difficult to treat. Finding BE, a sign... Read more

Surgical Techniques

view channel
Image: Novel surface treatment could prevent deadly hospital infections without antibiotics (Photo courtesy of Penn State)

Novel Surface Treatment Stops Microbes from Adhering to Medical Devices

Hospitals and medical clinics can be the source of nasty infections, resulting in death from infection-related complications and billions in direct medical costs. The biggest culprits, experts say - accounting... Read more

Health IT

view channel
Image: AI can reveal a patient`s heart health (Photo courtesy of Mayo Clinic)

AI Trained for Specific Vocal Biomarkers Could Accurately Predict Coronary Artery Disease

Earlier studies have examined the use of voice analysis for identifying voice markers associated with coronary artery disease (CAD) and heart failure. Other research groups have explored the use of similar... Read more
Copyright © 2000-2022 Globetech Media. All rights reserved.